# Personalized Neoantigen Peptide Vaccines for Solid Tumors

Source: https://onco.cc/trials/nct07002203/  
OnCo record `nct07002203` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Personalized Neoantigen Peptide Vaccine in advanced solid tumours, run by Seqker Biosciences, Inc., now recruiting.

## Summary

Personalized Neoantigen Peptide Vaccines for Solid Tumors is a phase 1/2 interventional study registered as NCT07002203 by Seqker Biosciences, Inc., with 10 participants planned, started 2024-03-01 and due to reach its primary completion in 2027-08. Interventions recorded: Personalized Neoantigen Peptide Vaccine.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07002203
- Phase: 1/2
- Setting: A Phase Ib Clinical Study of Personalized Neoantigen Peptide Vaccines for Solid Tumors
- Sponsor: Seqker Biosciences, Inc.
- Enrolled: 10

## Sources

- ClinicalTrials.gov NCT07002203: https://clinicaltrials.gov/study/NCT07002203

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct07002203.json